National Cancer Institute (NCI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Cancer Institute (NCI) sits in the top decile of US sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count).
National Cancer Institute (NCI): 3,257 sponsored US clinical trials, 326 recruiting.
National Cancer Institute (NCI) sponsors 3,257 registered US clinical trials on ClinicalTrials.gov, 326 of them currently recruiting, and 2,051 completed. 193 of these trials are in Phase 3-4 (later-stage) and 2,628 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignant Solid Neoplasm, with 67 trials.
Top-decile sponsor footprint
National Cancer Institute (NCI) ranks in the top decile of sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
3,257 total, page 45 of 66
Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes
NCT00104962
Genetic Analysis of Patients With Pseudoxanthoma Elasticum
NCT00341419
Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer
NCT00238121
FR901228 in Treating Patients With Metastatic Breast Cancer
NCT00098397
17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma
NCT00117988
SJG-136 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
NCT00121290
EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial Cancer
NCT00107445
17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
NCT00118092
Role of Gene Variation in Effectiveness of Gleevec Treatment
NCT00342056
Cilengitide in Treating Patients With Prostate Cancer
NCT00121238
Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery
NCT00114179
Cilengitide in Treating Patients With Metastatic Prostate Cancer
NCT00103337
FR901228 in Treating Patients With Recurrent High-Grade Gliomas
NCT00085540
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
NCT00101348
SB-715992 in Treating Patients With Advanced or Metastatic Colorectal Cancer
NCT00103311
Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme
NCT00112866
Study of Adult T-Cell Leukemia/Lymphoma Among Carriers of HTLV-1
NCT00339638
Surgery for Pancreatic Tumors and Collection of Tumor Tissue for Study
NCT00100321
Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer
NCT00118235
Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
NCT00114244
Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer
NCT00103298
Markers for Breast Cancer
NCT00339248
Radiotherapy Combined With Oxaliplatin and Fluorouracil Followed By Gemcitabine in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer
NCT00096070
Caspofungin to Prevent Candidiasis in Adults in Hospital Intensive Care Units
NCT00099775
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
NCT00104871
Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00098540
Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer
NCT00118248
BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer
NCT00098254
S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer
NCT00103324
Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma
NCT00093613
SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes
NCT00098826
Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical Resection
NCT00087269
Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma
NCT00088881
An Epidemiological Study of Genetic Risk Factors for Prostate Cancer in African-American and Caucasian Males
NCT00342771
MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
NCT00101179
BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors
NCT00095459
A Phase I Feasibility Study of an Intraprostatic PSA-Based Vaccine in Men With Prostate Cancer With Local Failure Following Radiotherapy or Cryotherapy or Clinical Progression on Androgen Deprivation Therapy in the Absence of Local Definitive Therapy
NCT00096551
Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors
NCT00100880
Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes
NCT00098423
Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma
NCT00099047
Detecting Abnormal Blood Clotting in Patients With Metastatic Cancer Undergoing Surgery
NCT00096590
Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer
NCT00100841
Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT00096447
Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery
NCT00101036
SJG-136 in Treating Patients With Advanced Solid Tumors
NCT00103220
Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
NCT00096005
Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
NCT00101205
SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma
NCT00101244
The Effects of Genetic Differences Among AIDS Patients on Cytomegalovirus Retinitis
NCT00341172
Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum
NCT00094978
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1199 |
| Phase 2 | 1429 |
| Phase 3 | 193 |
Therapeutic Areas
What is open in the National Cancer Institute (NCI) pipeline
326 recruiting of 3,257 indexed (10% open); 2,051 completed (63%).
Phase mix: 193 late (III/IV) vs 2,628 early (I/II) (early-phase heavy).
Top condition: Advanced Malignant Solid Neoplasm (67 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.